Barry Jones
About
In The Last Decade
Barry Jones
119 papers receiving 5.4k citations
Hit Papers
Peers
Comparison fields: 5 of 164
- Immunology 2.1k
- Molecular Biology 1.9k
- Oncology 927
- Cellular and Molecular Neuroscience 926
- Radiology, Nuclear Medicine and Imaging 641
Countries citing papers authored by Barry Jones
This map shows the geographic impact of Barry Jones's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Barry Jones with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Barry Jones more than expected).
Fields of papers citing papers by Barry Jones
This network shows the impact of papers produced by Barry Jones. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Barry Jones. The network helps show where Barry Jones may publish in the future.
Co-authorship network of co-authors of Barry Jones
This figure shows the co-authorship network connecting the top 25 collaborators of Barry Jones. A scholar is included among the top collaborators of Barry Jones based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Barry Jones. Barry Jones is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 11 | |
| 2 | 9 | |
| 3 | 94 | |
| 4 | 75 | |
| 5 | 70 | |
| 6 | Immune mechanism of action of talabostat: a dipeptidyl peptidase targeted antitumor agent | 6 |
| 7 | Characterization of innate effector cells involved in the anti-tumor activity of talabostat (PT-100) | 3 |
| 8 | Inhibitors of the stromal protease fibroblast activation protein attenuate tumor growth in vivo | 3 |
| 9 | Enhanced anti-tumor activity of dipeptidyl peptidase inhibitor PT-100 in combination with chemotherapy in mice. | 1 |
| 10 | 28 | |
| 11 | 20 | |
| 12 | 224 | |
| 13 | 4 | |
| 14 | 43 | |
| 15 | 36 | |
| 16 | 26 | |
| 17 | 11 | |
| 18 | 36 | |
| 19 | Rabbit anti-EL4 serum. A reagent which discriminates between murine cytotoxic and suppressor cells. | 3 |
| 20 | 30 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.